Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMarjorie Monleauen_US
dc.contributor.authorAvelin F. Aghokengen_US
dc.contributor.authorSabrina Eymard-Duvernayen_US
dc.contributor.authorAnoumou Dagnraen_US
dc.contributor.authorDramane Kaniaen_US
dc.contributor.authorNicole Ngo-Giang-Huongen_US
dc.contributor.authorCoumba Touré-Kaneen_US
dc.contributor.authorLien X.T. Truongen_US
dc.contributor.authorMarie Laure Chaixen_US
dc.contributor.authorEric Delaporteen_US
dc.contributor.authorAhidjo Ayoubaen_US
dc.contributor.authorMartine Peetersen_US
dc.description.abstractDried blood spots (DBS) can be used in developing countries to alleviate the logistic constraints of using blood plasma specimens for viral load (VL) and HIV drug resistance (HIVDR) testing, but they should be assessed under field conditions. Between 2009 and 2011, we collected paired plasma-DBS samples from treatment-experienced HIV-1-infected adults in Burkina Faso, Cameroon, Senegal, Togo, Thailand, and Vietnam. The DBS were stored at an ambient temperature for 2 to 4 weeks and subsequently at-20°C before testing. VL testing was performed on the plasma samples and DBS using locally available methods: the Abbott m2000rt HIV-1 test, generic G2 real-time PCR, or the NucliSENS EasyQ version 1.2 test. In the case of virological failure (VF), i.e., a plasma VL of>1,000 copies/ml, HIVDR genotyping was performed on paired plasma-DBS samples. Overall, we compared 382 plasma-DBS sample pairs for DBS VL testing accuracy. The sensitivities of the different assays in different laboratories for detecting VF using DBS varied from 75% to 100% for the m2000rt test in labs B, C, and D, 91% to 93% for generic G2 realtime PCR in labs A and F, and 85% for the NucliSENS test in lab E. The specificities varied from 82% to 97% for the m2000rt and NucliSENS tests and reached only 60% for the generic G2 test. The NucliSENS test showed good agreement between plasma and DBS VL but underestimated the DBS VL. The lowest agreement was observed for the generic G2 test. Genotyping was successful for 96/124 (77%) DBS tested, and 75/96 (78%) plasma-DBS pairs had identical HIVDR mutations. Significant discrepancies in resistance interpretations were observed in 9 cases, 6 of which were from the same laboratory. DBS can be successfully used as an alternative to blood plasma samples for routine VL and HIVDR monitoring in African and Asian settings. However, the selection of an adequate VL measurement method and the definition of the VF threshold should be considered, and laboratory performance should be monitored. Copyright © 2014, American Society for Microbiology. All Rights Reserved.en_US
dc.titleField evaluation of dried blood spots for routine HIV-1 viral load and drug resistance monitoring in patients receiving antiretroviral therapy in Africa and Asiaen_US
article.title.sourcetitleJournal of Clinical Microbiologyen_US
article.volume52en_US Translationnelles sur le VIH et les Maladies Infectieusesen_US de Recherche pour le Developpement Cameroonen_US MURAZen_US Mai Universityen_US de Bactériologie-Virologieen_US Trang Pasteur Instituteen_US Paris Descartesen_US Institut de Genetique Moleculaire de Montpellieren_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.

Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.